Poland – Antineoplastic agents – Dostawa produktów leczniczych z programów lekowych określonych w 10 pakietach.

Package No 1: Benralizumab, solution for injection 30 mg 1 x 1 injector 1 ml, op. 1200; Package No 2: /1. Dupilumab, solution for injection, 200 mg 2 x 1.14 ml injectors, op. 200; /2. Dupilumab, solution for injection, 300 mg 2 x 2 ml injectors, op. 350; Package No 3: /1. Amivantamab, concentrate for solution for infusion, 350 mg 1 x 7 ml vial, op. 400; /2. Amivantamab, solution for injection, 1600 mg 1 x 10 ml vial, op. 150; /3. Amivantamab, solution for injection, 2240 mg 1 x 14 ml vial, op. 100; Package No 4: /1. Lazertinib, coated tab. 80 mg, 56 pcs, op. 50; /2. Lazertinib, coated tab. 240 mg 28 pcs, op. 100; Package No 5: Mepolizumab, solution for injection, 100mg 1 x 1 injector, op. 2500; Package No 6: Tezepelumab, solution for injection in injector, 210 mg, 1 x 1.91 ml, op. 450; Package No 7: /1. Omalizumab, solution for injection, 75 mg 1 x 1 injector, op. 30; /2. Omalizumab, solution for injection, 150 mg 1 x 1 injector, op. 600; Package No 8: Ondansetron, 2 mg/ml solution for injection, 2 mg/ml, 5 x 4 ml amp, op. 3500; Package No 9: Infliximab, powder for concentrate for solution for infusion, 100 mg, 1 x 1 vial, op. 600; Package No 10: /1. Afatinib, coated tab. 20 mg 28 pcs, op. 10; /2. Afatinib, coated tab. 30 mg 28 pcs, op. 15; /3. Afatinib, coated tab. 40 mg 28 pcs, op. 10.